AI-driven new drug discovery company AnHorn Medicines announced on Wednesday that AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has commenced a Phase I clinical trial in the United States.

AH-001 is an advancement in AGA treatment with a novel mechanism of action as a selective protein degrader that precisely targets and eliminates key proteins linked to hair loss.

According to AnHorn, this innovative approach has the potential to offer a more effective and long-lasting solution for millions of individuals suffering from AGA worldwide.

Current AGA treatments, such as finasteride and minoxidil, have limitations in efficacy and potential side effects, leaving a significant unmet medical need.